Table 4 Status of methotrexate use

Safety analysis population

82

Concomitant use of MTX

No

26

(31.7)

Yes^a

56

(68.3)

MTX was used at the start of treatment with abatacept

56

(100.0)

MTX was not discontinued during treatment with abatacept

46

(82.1)

MTX dose was ultimately increased during treatment with abatacept

2

(3.6)

MTX dose was not changed during treatment with abatacept

35

(62.5)

MTX dose was ultimately reduced during treatment with abatacept

9

(16.1)

MTX was discontinued during treatment with abatacept

9

(16.1)

MTX was discontinued due to an adverse event

4

(7.1)

Unknown whether MTX was discontinued during the treatment period

1

(1.8)

Treatment with MTX was started during treatment with abatacept

0

(0.0)